Ipsen announces investment in new state-of-the-art electronic autoinjector for Somatuline® Autogel® / Somatuline® Depot (lanreotide) designed to improve patient experience.

  • New electronic autoinjector is designed to improve patient experience for people living with gastroenteropancreatic neuroendocrine tumors, carcinoid syndrome or acromegaly
  • Performance and safety studies ongoing, with first launches for the new device expected in 2024
  • A fourth generation Somatuline® Autogel® / Somatuline® Depot device building on Ipsen’s 20 years’ heritage to date

Read the full press release: